Aldevron to Build 14-Acre Gene Therapy Manufacturing Campus

• August ground breaking of second GMP manufacturing facility

• Expands GMP and GMP Source^TM plasmid capacity 10-fold

• Supports gene editing, gene therapy, and cell therapy applications

• Includes synthetic production of nucleic acids, vertical integration for clients

FARGO, N.D. (June 3, 2019) – Aldevron, a leader in the production of plasmid DNA, proteins, mRNA and antibodies; announced today expansion plans for a 14-acre campus at its headquarters in Fargo, N.D. Phase one construction will begin in August. Upon completion of the campus, the annual capacity will exceed $1 Billion of plasmid DNA, RNA, gene editing enzymes, and other biologics.

The first two-story building will increase Aldevron’s GMP and GMP-Source^TM production capacity up to 10 times its current output. This 189,000 square-foot new build will connect to the existing GMP facility and is expected to be fully operational by Q1 of 2021. In total, three new buildings are slated to be built over the next three to five years to support the rapidly growing field of genetic medicine.

“This plan is designed to serve the biopharmaceutical industry with the world’s most advanced manufacturing platforms for gene and cell therapy,” said Michael Chambers, CEO of Aldevron. “It is an honor for us to provide plasmids, gene editing enzymes, and other biologics to support clinical and commercial applications that our clients are pioneering.” Chambers added that the new campus will also enable large-scale production of novel products like nanoplasmids and minicircles.

 “Our industry is growing exponentially. We are building a campus to meet client demand, create a functional and inspiring environment for our staff, and take us to the next level,” said Henry Hebel, Chief Operating Officer for Aldevron. “Our robust expansion plan was designed by listening to and engaging with regulatory agencies, industry professionals and most importantly, our clients. The design decisions promote efficiency and scaling, and the next generation of manufacturing optimization.”

Plans include adding 20,000 square-feet of additional Quality Control and product storage space to Aldevron’s current 70,000 square-foot GMP and GMP-Source^TM manufacturing building, the world’s largest plasmid DNA manufacturing facility, which opened in September 2018. The next building to be added is an 89,000 square-foot, two-story administration and client visit center, connected to the manufacturing space via skyway. The final building will be a 96,000 square-foot research and development, technical operations and training center. Once complete, the total square footage will be nearly 0.5 million square feet and has potential to employ 1,000 people.

“Our mission has remained unchanged in 21 years: to help our clients improve lives through innovative partnerships and scientific excellence,” continued Chambers. “This campus has been, and will continue to be, designed to serve their current and future breakthroughs.”

Aldevron is a privately held company, founded in 1998. Its biologics are currently being used by thousands of researchers around the world who are improving the lives of millions. Aldevron’s expansion plan adds the necessary capacity and flexibility to support those discoveries with Research Grade, GMP-Source^TM and GMP nucleic acids, proteins and mRNA. The company currently employs more than 350 people across its current global network in Fargo, Madison, WI, and Freiburg, Germany.